Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026

Opus Genetics, Inc.

Opus Genetics, Inc.

IRD

0.00
  • Opus Genetics set a timeline for OPGx-BEST1 Phase 1/2 BIRD-1 Cohort 1 results, a potential material catalyst for the BEST1 gene therapy program.
  • Three-month topline data from Cohort 1 expected in the second week of September 2026, subject to scheduled participant assessments.
  • Data slated for presentation at the EURETINA Congress in Vienna on Oct. 1-4, 2026.
  • Trial progression hinges on Month 3 safety plus OCT subretinal fluid changes; ~20% reduction viewed as clinically meaningful for advancing to Cohort 2.
  • Majority 100% fluid reduction could support expansion into a potential pivotal trial; investor relations quiet period starts July 15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090700PRIMZONEFULLFEED9759343) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.